Selinexor Produces Responses in HMA-Refractory MDS, Oligoblastic AML
Selinexor yields responses in patients with MDS or oligoblastic AML refractory to hypomethylating agents, with manageable adverse events.
Hematologic Cancers
Incorporating Immunotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
Real-World Data Show Temporal Trends in Risk of Serious Bacterial Infections in Patients With CLL
These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.
Risk-Stratified Treatments May Offer Cures in Relapsed Pediatric Anaplastic Large Cell Lymphoma
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
No Benefit From Early Rituximab Intensification During DLBCL Treatment
Researchers in the Netherlands conducted HOVON-84 to determine what benefit, if any, early rituximab intensification had in adult patients with untreated DLBCL.
Long-Term Zanubrutinib Treatment Effective for Majority of Patients With Waldenström Macroglobulinemia
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Risk-Stratified Therapy Reduces Late Morbidity, Mortality in Pediatric Acute Lymphoblastic Leukemia
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Venetoclax With Chemotherapy: Promising for Elderly Patients With AML?
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
